Insurers and state Medicaid agencies have been eager to strike a deal with pharmaceutical companies to secure discounts on pricey hepatitis C drugs.
Both insurers and state Medicaid agencies are working to secure discounts on pricey hepatitis C drugs.
Insurers and states alike have been eager to strike a deal with the pharmaceutical companies, especially considering
the backlash Gilead's Sovaldi received last year after the company placed a $100,000 per person price tag on the drug. Harvoni is Gilead's follow-up to Sovaldi.
Missouri signed a deal with AbbVie this week to make Viekira Park the preferred drug covered by the state's Medicaid program, noted the Wall Street Journal
. The drug will replace Sovaldi. AbbVie will "provide a rebate to states participating in the consortium."
Read more: http://bit.ly/15UL9hm
Source: Fierce Health Payer
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen